Clinical Policy: Mitoxantrone
Medical necessity and prior authorization criteria for mitoxantrone use across multiple indications (multiple sclerosis, prostate cancer, acute leukemias, and select off-label hematologic malignancies) for members of the payer lines of business.
For pediatric BCR::ABL1-negative B-ALL, added requirement for use as a component of UKALL R3 or COG AALL 1331 per NCCN; removed B-cell lymphomas as coverable diagnoses.
For MS, removed requirements for documentation of baseline relapses/EDSS and specific measures of positive response; increased Medicaid/HIM continued approval duration from 6 to 12 months.
Removed references to brand Novantrone and removed mantle cell lymphoma as a coverable B-cell lymphoma; clarified coverable ALL types per NCCN.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.